Aberdeen Group plc Makes New $9.02 Million Investment in Revolution Medicines, Inc. $RVMD

Key Points

• Aberdeen Group opened a new position in Revolution Medicines, buying 113,268 shares worth about $9.02 million, representing roughly 0.06% of the company; institutional investors now own about 94.34% of the stock.
• Analyst sentiment is broadly positive—MarketBeat shows a consensus rating of "Buy" with a consensus price target of $78.94—notably below the recent share price (opened at $96.29), indicating mixed valuation views despite multiple Buy/Strong Buy endorsements.
• Fundamentals and insider activity: the company reported Q4 EPS of ($1.86), missing estimates, has a market cap of about $19.08 billion, and insiders have sold roughly $6.49 million of stock in the past 90 days (insiders own 8.20%).

Aberdeen Group plc purchased a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 113,268 shares of the company's stock, valued at approximately $9,022,000. Aberdeen Group plc owned about 0.06% of Revolution Medicines as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its holdings in Revolution Medicines by 45.1% during the 3rd quarter. GAMMA Investing LLC now owns 837 shares of the company's stock valued at $39,000 after purchasing an additional 260 shares during the last quarter. Danske Bank A S bought a new position in Revolution Medicines during the 3rd quarter valued at about $98,000. FNY Investment Advisers LLC bought a new position in Revolution Medicines during the 3rd quarter valued at about $110,000. Wealth Enhancement Advisory Services LLC bought a new position in Revolution Medicines during the 4th quarter valued at about $208,000. Finally, US Bancorp DE lifted its holdings in Revolution Medicines by 170.3% during the 3rd quarter. US Bancorp DE now owns 3,168 shares of the company's stock valued at $148,000 after purchasing an additional 1,996 shares during the last quarter. 94.34% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on RVMD shares. Benchmark restated an "overweight" rating on shares of Revolution Medicines in a report on Tuesday, February 17th. Jefferies Financial Group started coverage on Revolution Medicines in a report on Monday, March 16th. They set a "buy" rating on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Revolution Medicines in a report on Thursday, January 22nd. Wedbush restated an "outperform" rating on shares of Revolution Medicines in a report on Friday, January 9th. Finally, Truist Financial upgraded shares of Revolution Medicines to a "strong-buy" rating in a research report on Wednesday, March 25th. Five investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $78.94.

Revolution Medicines Stock Up 1.0%

Shares of NASDAQ RVMD opened at $96.29 on Wednesday. The firm has a market capitalization of $19.08 billion, a PE ratio of -16.29 and a beta of 1.01. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.16. Revolution Medicines, Inc. has a 1 year low of $29.98 and a 1 year high of $124.49. The firm's 50-day moving average is $98.18 and its 200-day moving average is $81.78.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same quarter in the prior year, the company earned ($1.12) EPS. Equities analysts expect that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Insider Buying and Selling

In related news, CFO Jack Anders sold 2,753 shares of the company's stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $273,868.44. Following the completion of the sale, the chief financial officer owned 125,512 shares in the company, valued at approximately $12,485,933.76. This represents a 2.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Margaret A. Horn sold 4,583 shares of the company's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $455,916.84. Following the completion of the sale, the chief operating officer owned 157,570 shares of the company's stock, valued at $15,675,063.60. This represents a 2.83% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 64,592 shares of company stock worth $6,488,732. 8.20% of the stock is currently owned by company insiders.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.